InVivo Therapeutics Holdings Corp. (NVIV) today announced that
the abstract “Biodegradable Neuro-Spinal Scaffold Preserves Macroscopic
Spinal Cord Architecture and Allows for Neural Regeneration at the
Spinal Cord Contusion Epicenter” has been accepted for presentation at
the 2015 Tissue Engineering & Regenerative Medicine International
Society (TERMIS) World Congress to be held September 8-11, 2015 in
Boston, MA. Alex Aimetti, Ph.D., Senior Director, Medical Education and
Scientific Support, will be giving the poster presentation. The abstract
is co-authored by Dr. Aimetti, Richard Layer, Ph.D., Simon Moore, Ph.D.,
and Thomas Ulich, M.D.
Mark Perrin, InVivo’s CEO and Chairman, said, “Making meaningful and
significant progress in the treatment of spinal cord injury continues to
be our core mission at InVivo. This progress remains the fundamental
value driver for our company, and I look forward to reporting on further
achievements made by our scientific and clinical teams.”
About the Neuro-Spinal Scaffold
Following an acute spinal cord injury, the biodegradable Neuro-Spinal
Scaffold is surgically implanted at the epicenter of the wound and is
designed to act as a physical substrate for nerve sprouting.
Appositional healing to spare spinal cord tissue, decreased
post-traumatic cyst formation, and decreased spinal cord tissue pressure
have been demonstrated in preclinical models of spinal cord contusion
injury. The Neuro-Spinal Scaffold, an investigational device, has
received a Humanitarian Use Device (HUD) designation and is currently
being studied in an Investigational Device Exemption (IDE) pilot study
for the treatment of patients with complete (AIS A) traumatic acute
spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage
biomaterials and biotechnology company with a focus on treatment of
spinal cord injuries. The company was founded in 2005 with proprietary
technology co-invented by Robert Langer, Sc.D., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
then was at Boston Children’s Hospital and who now is affiliated with
Massachusetts General Hospital. In 2011, the company earned the David S.
Apple Award from the American Spinal Injury Association for its
outstanding contribution to spinal cord injury medicine. In 2015, the
company’s investigational Neuro-Spinal Scaffold received the 2015
Becker’s Healthcare Spine Device Award. The publicly-traded company is
headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements within the
meaning of the federal securities laws. These statements can be
identified by words such as “believe,” “anticipate,” “intend,”
“estimate,” “will,” “may,” “should,” “expect,” “designed to,”
“potentially,” and similar expressions, and include statements regarding
the company’s strategy and expected benefits, efficacy and future
clinical outcomes of its treatments for spinal cord injury. Any
forward-looking statements contained herein are based on current
expectations, and are subject to a number of risks and uncertainties.
Factors that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the company’s ability to successfully open
additional clinical sites for enrollment and to enroll additional
patients; the timing of the Institutional Review Board process; the
company’s ability to obtain FDA approval to modify its pilot trial
protocol or to conduct a future study; the company’s ability to
commercialize its products; the company’s ability to develop, market and
sell products based on its technology; the availability of substantial
additional funding for the company to continue its operations and to
conduct research and development, clinical studies and future product
commercialization; and other risks associated with the company’s
business, research, product development, regulatory approval, marketing
and distribution plans and strategies identified and described in more
detail in the company’s Annual Report on Form 10-K for the year ended
December 31, 2014, and its other filings with the SEC, including the
company’s Form 10-Qs and current reports on Form 8-K. The company does
not undertake to update these forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150831005394/en/
Copyright Business Wire 2015